Navigation Links
Malaria: New Treatment is Upcoming

ROME, January 16 /PRNewswire/ -- The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment. The DHA/PQP combination is very well tolerated with no significant side effects.

These notable results were presented at the 57th Annual Meeting of the American Society of Tropical Medicine & Hygiene (ASTMH) held in New Orleans, Louisiana, USA, (December 7-11, 2008). The results demonstrate the benefits of a treatment which is effective against a neglected disease contracted by 400-500 million people worldwide every year and the cause of death of over 1 million people, sadly largely children under 5 in Sub-Saharan Africa.

"If not promptly and effectively treated, malaria can kill in just a few days after the onset of symptoms," said Prof. Umberto D'Alessandro, Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium, coordinator of one of the trials. "This novel medication expands the treatment arsenal available to us, delivers immediate benefits because it acts rapidly, and unquestionably provides help to the populations of Africa and Asia, who are the hardest hit by the disease, but also to Westerners who visit those countries for business or pleasure."

Developed by sigma-tau, the new ACT meets WHO clinical evidence-based treatment strategy recommendation as it is a medication combining in a single tablet the highly potent artemisinin-based active ingredient which does not stay long in the body with a second antimalarial which stays longer in the body. This combination treatment is to be taken only for three days and facilitates the mutual protection of the two active ingredients against drug resistance.

The results presented in New Orleans come from a development program for worldwide drug approval. The most important trials in the program were two large phase III comparative clinical trials conducted in Africa (Burkina Faso, Zambia, Kenya, Mozambique and Uganda) and Asia (Thailand, India and Laos) respectively, which involved a total of about 2,700 patients, of whom 1,600 children under 5, all with uncomplicated malaria caused by Plasmodium falciparum, the most widespread and dangerous parasite and the cause of the highest mortality in infected individuals.

"The new data," said Claudio Cavazza, sigma-tau Chairman. "Confirm the huge potential of this new combination which may become the gold standard in malaria treatment in all those countries where fatal drug-resistance has been observed with conventional antimalarials. Our hope is that the joint efforts made to develop this new drug and make it available to the greatest possible number of patients will substantially contribute to the achievement of the ambitious goal of the Gates Foundation to eliminate and ultimately fully eradicate malaria. The extremely positive results of the clinical trials make us hope the drug will rapidly receive marketing approval. The NDA is expected to be filed with the EMEA and the FDA around mid-2009, so that the drug can be made available as soon as possible not only in Europe and the United States, but also in all those countries where malaria is endemic."

sigma-tau's commitment began to become tangible in 2004 when the company entered into a partnership with Medicines for Malaria Venture, the Geneva-based non-profit organization created to discover, develop and deliver effective and affordable antimalarial drugs through public-private partnerships, supported primarily by the Bill & Melinda Gates Foundation and the University of Oxford.

About sigma-tau

sigma-tau is a leading, all Italian capital, international pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve patient well-being and quality of life.

sigma-tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, the Netherlands, Portugal, Germany, the UK and the USA, as well as in Spain and Sudan where the Group operates two production facilities. It has over 2500 employees and an extensive network of licensees worldwide.

sigma-tau was founded in Italy in 1957 and achieved a global turnover of EUR 665 million ($ 920 million) in 2007.

sigma-tau SpA consistently invests 16% of its annual turnover in R&D. sigma-tau's 400 R&D staff are currently running 43 R&D projects. A total of 14 NCEs and 12 known molecular entities in 30 different indications are at various stages of development.

Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology.

    sigma-tau website:
    For further information:

    Press Office
    Publicis Consultants Italia
    Virginie Colonna-Foschi
    Mobile. +39-349-8762101
    Tel. +39-02-7632091
    Fax +39-02-76320940

SOURCE sigma-tau
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
4. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
5. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
6. Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
7. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
8. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
9. Vasomotor Symptoms? Create an Individual Treatment Plan for Your Patient
10. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
11. provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... ... 24, 2015 , ... Creation Technologies would like to extend ... 2015 Technology Fast 500 list of the fastest growing companies in North America. ... medical device that speeds up orthodontic tooth movement by as much as 50 ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
Breaking Biology Technology:
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):